FilingSEC EDGAR8-K
Gain Therapeutics Announces Long-Term Phase 1b Data for Rexaceract in Parkinson's Disease
· SEC accepted
StagePhase 1b
Filing content
The company reported stable motor symptoms in a 12-month Phase 1b open-label extension study for rexaceract and plans to initiate a Phase 2 trial in Q1 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…